These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7290952)

  • 21. [Successful treatment with cladribine for hypoplastic hairy cell leukemia after long-term neutropenia].
    Sakai R; Yamazaki E; Sakamoto H; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2005 Nov; 46(11):1187-90. PubMed ID: 16440801
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hairy-cell leukemia: a rare blood disorder in Asia.
    Josephine FP; Nissapatorn V
    Southeast Asian J Trop Med Public Health; 2006; 37 Suppl 3():190-4. PubMed ID: 17547079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Bone marrow fibrosis during therapy of hairy cell leukemia].
    Dĕdic K; Zák P
    Cesk Patol; 2004 Jan; 40(1):22-4. PubMed ID: 15035057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
    Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cladribine in hairy cell leukemia.
    Belani R; Saven A
    Hematol Oncol Clin North Am; 2006 Oct; 20(5):1109-23. PubMed ID: 16990111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
    Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
    Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hairy cell leukemia. II.--Critical review of literature. Part. 1:diagnosis and evolution (author's transl)].
    Bernadou A
    Sem Hop; 1981 Sep 18-25; 57(33-36):1366-71. PubMed ID: 6270795
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 2-CdA in the treatment of hairy cell leukaemia.
    Abhyankar D; Bajpai S; Saikia T; Gopal R; Nair CN; Advani SH
    J Assoc Physicians India; 2001 Aug; 49():785-7. PubMed ID: 11837464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine).
    Füreder W; Weltermann A; Chott A; Gisslinger H; Valent P; Jäger U; Geissler K; Lechner K
    Wien Klin Wochenschr; 1999 Dec; 111(24):1027-30. PubMed ID: 10677889
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trials of pentostatin (Nipent) in hairy cell leukemia.
    Kraut EH
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):27-31. PubMed ID: 10877048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dyserythropoietic changes and sideroblastic anemia in patients with hairy cell leukemia before and after therapy with 2-chlorodeoxyadenosine.
    Zák P; Chrobák L; Podzimek K; Plísková L; Dedic K
    Neoplasma; 1998; 45(4):261-5. PubMed ID: 9890671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study.
    Johnston JB; Eisenhauer E; Wainman N; Corbett WE; Zaentz SD; Daeninck PJ
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):32-6. PubMed ID: 10877049
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Successful use of cladribine in the treatment of an elderly woman with typical hairy cell leukemia].
    Terasaki Y; Okumura H; Hirose A; Ishiura Y; Yokawa S; Saito K; Nakao S
    Gan To Kagaku Ryoho; 2007 Nov; 34(11):1885-8. PubMed ID: 18030031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Flow cytometry of peripheral blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells, lymphocyte subsets and detection of minimal residual disease after treatment.
    Babuŝíková O; Tomová A; Kusenda J; Gyárfás J
    Neoplasma; 2001; 48(5):350-7. PubMed ID: 11845978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Complete remission after Rituximab treatment in refractory hairy cell leukemia].
    Petruskevicius I; Bukh A; Mertz H; Johnsen HE
    Ugeskr Laeger; 2008 Jun; 170(26-32):2350. PubMed ID: 18570771
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effectiveness of rubidazone in hairy cell leukemia (leukemic reticuloendotheliosis).
    Stewart DJ; Benjamin RS; McCredie KB; Murphy S; Keating M
    Blood; 1979 Aug; 54(2):298-304. PubMed ID: 454838
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hairy cell leukemia. II.--Critical review of literature. Part 2: the hairy cell origin (author's transl)].
    Bernadou A
    Sem Hop; 1981 Sep 18-25; 57(33-36):1380-5. PubMed ID: 6270796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and molecular complete remission in a case of variant hairy cell leukemia treated with DHAP followed by high-dose chemotherapy plus rituximab.
    Goldaniga M; Guffanti A; Gianelli U; Magni M; Lambertenghi Deliliers G; Baldini L
    Haematologica; 2004 Nov; 89(11):ECR41. PubMed ID: 15533846
    [No Abstract]   [Full Text] [Related]  

  • 40. [Acute osteomyelofibrosis. An overview and 2 personal cases].
    Strebel U; Schaffner A; Fehr J
    Schweiz Med Wochenschr; 1983 Jun; 113(23):844-50. PubMed ID: 6576466
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.